These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 19196511

  • 1. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P, Taveras AG, Dwyer MP, Yu Y, Chao J, Hipkin RW, Fan X, Rindgen D, Fine J, Lundell D.
    Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1431-3. PubMed ID: 19196511
    [Abstract] [Full Text] [Related]

  • 2. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
    Aki C, Chao J, Ferreira JA, Dwyer MP, Yu Y, Chao J, Merritt RJ, Lai G, Wu M, Hipkin RW, Fan X, Gonsiorek W, Fosseta J, Rindgen D, Fine J, Lundell D, Taveras AG, Biju P.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4446-9. PubMed ID: 19525110
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, Rokosz LL, Kaiser B, Li G, Wang W, Stauffer T, Ozgur L, Baldwin J, Taveras AG.
    J Med Chem; 2006 Dec 28; 49(26):7603-6. PubMed ID: 17181143
    [Abstract] [Full Text] [Related]

  • 4. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
    Chao J, Taveras AG, Chao J, Aki C, Dwyer M, Yu Y, Purakkattle B, Rindgen D, Jakway J, Hipkin W, Fosetta J, Fan X, Lundell D, Fine J, Minnicozzi M, Phillips J, Merritt JR.
    Bioorg Med Chem Lett; 2007 Jul 01; 17(13):3778-83. PubMed ID: 17459706
    [Abstract] [Full Text] [Related]

  • 5. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P, Taveras A, Yu Y, Zheng J, Chao J, Rindgen D, Jakway J, Hipkin RW, Fossetta J, Fan X, Fine J, Qiu H, Merritt JR, Baldwin JJ.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):228-31. PubMed ID: 18006311
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.
    J Pharmacol Exp Ther; 2007 Aug 01; 322(2):477-85. PubMed ID: 17496166
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
    Yu Y, Dwyer MP, Chao J, Aki C, Chao J, Purakkattle B, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Qiu H, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, He Z, Lai G, Wu M, Taveras A.
    Bioorg Med Chem Lett; 2008 Feb 15; 18(4):1318-22. PubMed ID: 18242983
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
    Lai G, Merritt JR, He Z, Feng D, Chao J, Czarniecki MF, Rokosz LL, Stauffer TM, Rindgen D, Taveras AG.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):1864-8. PubMed ID: 18304809
    [Abstract] [Full Text] [Related]

  • 9. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
    Nie H, Widdowson KL, Palovich MR, Fu W, Elliott JD, Bryan DL, Burman M, Schmidt DB, Foley JJ, Sarau HM, Busch-Petersen J.
    Bioorg Med Chem Lett; 2006 Nov 01; 16(21):5513-6. PubMed ID: 16934456
    [Abstract] [Full Text] [Related]

  • 10. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
    Jin Q, Nie H, McCleland BW, Widdowson KL, Palovich MR, Elliott JD, Goodman RM, Burman M, Sarau HM, Ward KW, Nord M, Orr BM, Gorycki PD, Busch-Petersen J.
    Bioorg Med Chem Lett; 2004 Sep 06; 14(17):4375-8. PubMed ID: 15357956
    [Abstract] [Full Text] [Related]

  • 11. 3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.
    Biju P, Taveras AG, Yu Y, Zheng J, Hipkin RW, Fossetta J, Fan X, Fine J, Lundell D.
    Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1434-7. PubMed ID: 19200721
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
    Merritt JR, Rokosz LL, Nelson KH, Kaiser B, Wang W, Stauffer TM, Ozgur LE, Schilling A, Li G, Baldwin JJ, Taveras AG, Dwyer MP, Chao J.
    Bioorg Med Chem Lett; 2006 Aug 01; 16(15):4107-10. PubMed ID: 16697193
    [Abstract] [Full Text] [Related]

  • 13. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P.
    Eur Cytokine Netw; 2006 Mar 01; 17(1):35-41. PubMed ID: 16613761
    [Abstract] [Full Text] [Related]

  • 14. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.
    Pulm Pharmacol Ther; 2015 Oct 01; 34():37-45. PubMed ID: 26271598
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, Griswold DE, Martin L, Lee JM, White JR, Sarau HM.
    J Med Chem; 2004 Mar 11; 47(6):1319-21. PubMed ID: 14998320
    [Abstract] [Full Text] [Related]

  • 16. Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases.
    Matityahu E, Feniger-Barish R, Meshel T, Zaslaver A, Ben-Baruch A.
    Eur J Immunol; 2002 Dec 11; 32(12):3525-35. PubMed ID: 12442335
    [Abstract] [Full Text] [Related]

  • 17. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
    Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.
    J Pharmacol Exp Ther; 2007 Aug 11; 322(2):486-93. PubMed ID: 17496165
    [Abstract] [Full Text] [Related]

  • 18. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.
    Int Immunopharmacol; 2012 Jul 11; 13(3):225-31. PubMed ID: 22561413
    [Abstract] [Full Text] [Related]

  • 19. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
    Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, Mallinder PR.
    Mol Pharmacol; 2008 Nov 11; 74(5):1193-202. PubMed ID: 18676678
    [Abstract] [Full Text] [Related]

  • 20. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
    Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, Galliera E, Di Benedetto P, Vigilante P, Bertini R, Allegretti M.
    J Med Chem; 2007 Aug 23; 50(17):3984-4002. PubMed ID: 17665889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.